Last reviewed · How we verify

Randomization between two referenced treatments

University Hospital, Clermont-Ferrand · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Randomization between two referenced treatments is a Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved.

Randomization is a method used in clinical trials to compare two or more treatments, such as Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo) and Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin), by assigning participants to each treatment group randomly. This method, as seen in the clinical trial NCT01138514, helps to minimize bias and ensure that the groups being compared are similar in terms of demographic and clinical characteristics.

At a glance

Generic nameRandomization between two referenced treatments
SponsorUniversity Hospital, Clermont-Ferrand
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Randomization between two referenced treatments

What is Randomization between two referenced treatments?

Randomization between two referenced treatments is a Small molecule drug developed by University Hospital, Clermont-Ferrand.

Who makes Randomization between two referenced treatments?

Randomization between two referenced treatments is developed and marketed by University Hospital, Clermont-Ferrand (see full University Hospital, Clermont-Ferrand pipeline at /company/university-hospital-clermont-ferrand).

What development phase is Randomization between two referenced treatments in?

Randomization between two referenced treatments is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing